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to be diagnosed with advanced BC and to have the highest mortality rates and 
the poorest survival rates from BC. The purpose of the study is to determine the 
relationship among race, insurance, and BC death. METHODS: African Americans 
and Non-Hispanic Whites female BC patients diagnosed between 2007 and 2010 
in Florida, and treated at a network of 9 hospitals were identified by electronic 
medical record search. BC incidence cases were obtained from Florida Cancer 
Data System (FCDS) which is the largest population-based cancer incidence reg-
istry in the nation. FCDS cases were linked to Electronic Medical Records (EMRs). 
Cause specific survival was the major Outcome measure. Nonparametric survival 
curves for the various insurance categories were generated using the Kaplan-
Meier method. Socio-demographics included age at diagnosis, race, insurance, 
marital status, poverty level. Tumor characteristics consisted of tumor stage, 
tumor grade, tumor size, estrogen receptor status, progesterone receptor status. 
Risk of BC death was first examined as a function of insurance status. Hazard 
ratios were then obtained using Cox proportional hazards model after adjust-
ing for socio-demographics, tumor characteristics when associating insurance 
status with BC related death. RESULTS: Study population was older (74% more 
than 50 years old), had more whites, 55.55 % were married and included a greater 
proportion of patients on public coverage (46%). Survival was worse for uninsured 
patients than for privately insured patients with all stages. The adjusted risk 
of BC death was 40% higher for uninsured patients than for privately insured 
patients. CONCLUSIONS: Uninsured patients presented with worse survival than 
did privately insured patients. Findings from this study demonstrate that patients 
without insurance experience worse outcomes and would benefit the most from 
improved access to screening and optimal cancer care.
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OBJECTIVES: Peripheral arterial disease (PAD) is a high prevalence disease after 50 
years old, with considerable impact in quality of life, productivity, disability and 
longevity. Screening program for high risk populations followed by risk factors modi-
fication seems to be a cost effective strategy, but adherence to treatment is crucial 
to achieve clinical and financial goals. The aim of this study was to evaluate the 
minimal adherence rate, to risk factors drugs modification to achieve the return 
of investment for screening-management programs in the Brazilian public health 
system context. METHODS: a decision tree – return of investment model was devel-
oped in Excel® to analyze the impact of implementing a screening-management 
program for early detection and risk management modifications in peripheral arte-
rial disease. Effectiveness of drugs to control the risk factor and reduce the risk of 
major cardiovascular events and major leg events was extracted from literature. 
Direct costs included treatment cost, exams, physician visits and events (AMI and 
Stroke), indirect cost was calculated considering the loose of productivity. The sys-
tem overload with screening program, including physician visits and exams were 
considered in the model. RESULTS: Our hypothetical population was 2.844.201 
subjects from Rio de Janeiro city, with a prevalence of PAD after 55 years old of 
10% (133.185) and the prevalence of intermittent claudication of 5%(66.592). The 
total cost of implementing the screening-risk management program for the entire 
population was R$8.576.758.52, the financial equilibrium was achieved with full 
adherence of 46,3% of subjects, with a reduction of R$4.201.429,36 with system effi-
ciency improvement, R$4.395.630,65 with indirect costs reductions and R$738.565,00 
with direct costs reductions. CONCLUSIONS: A screening-risk factor management 
program for improve the quality of assistance for PAD is feasible in the Brazilian 
public health system context and achieve its equilibrium with full adherence to risk 
factor management of 46,3% of subjects.
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OBJECTIVES: This study analyzes the cost of adverse events associated with meta-
static renal cell carcinoma (mRCC) treatments of pazopanib and sunitinib. METHODS: 
A cost analysis was performed based on the published data of the COMPARZ study. 
All adverse events (AEs) were identified based on the AEs reported in this study, 
Cost information related to the the treatment of the most frequent adverse events 
(> 15%) in the study population (n= 1,100 individuals) were obtained. These events 
included in the analysis were hepatotoxicity, anemia, nausea, fatigue and diarrhea. 
The perspective adopted in this analysis was of the Unified Health System (SUS) and 
Brazilian Supplementary Healthcare (SS). For reckoning purposes, the Medication 
Market Regulation Chamber (CMED/ ANVISA) listed prices were used. RESULTS: 
Were obtained the following results for suninitib vs pazopanib treatment course 
respectively: In SUS perspective: Increased ALT (BRL 107,24 / BRL 149,63), Anemia 
(BRL 47,72 / BRL 24,65), Diarrhea (BRL 231,44 / BRL 255,8), Fatigue (BRL 22,67 / BRL 
19,79), Hypertension (BRL 618,79 / BRL 694,26), Nausea (BRL 176,49 / BRL 172,65), 
Thrombocytopenia (BRL 66,29 vs BRL 34,85). When considering costs incurred 
from private pay perspective such as SS, we observed the values were Increased 
ALT (BRL 810,84 / BRL 1131,40), Anemia (BRL 269,31 / BRL 139,14), Diarrhea (BRL 
787,41 vs BRL 870,29), Fatigue (BRL 205,51 / BRL 179,42), Hypertension (BRL 1017,91 
/ BRL 1142,04), Nausea (BRL 782 / BRL 765), Thrombocytopenia (BRL 328,49 / BRL 
172,67). CONCLUSIONS: A therapy that has less financial impact on the treatment of 
adverse events is the choice of sunitinib for both public (6% decrease) and private (5%).
OBJECTIVES: To estimate burden of disease of hepatitis C (HVC) infection in 
Colombia METHODS: Different research methodologies were uses: system-
atic literature review methodology to identify parameters of disease frequency 
described in national and international studies. For all calculations the popula-
tion of Colombia was taken as projections National Administrative Department 
of Statistics. Other important source of information was the burden of disease 
studies conducted by the Institute for Health Metrics and Evaluation (IHME) at the 
University of Washington. RESULTS: In Colombia are estimated between 250,000 
and 350,000 people HCV carriers, currently. Of these, annually are attended in the 
General System of Social Security in Health, between 1100 and 1500 patients. The 
deaths expected by Liver cirrhosis secondary to hepatitis C are between 1,400 and 
1,600. By other side, the deaths annually associated with Liver Cancer related with 
Hepatitis C are between 750 and 850 deaths. This would generate about 40,000 and 
55,000 DALYs representing the between 84.8 and 106.1 DALYs per 100,000 people in 
Colombia in 2014. CONCLUSIONS: The burden of disease Hepatitis C in Colombia 
show that it is a public health problem important for the health system and society.
PHS21
examining riSk factorS and Predicting readmiSSionS in coPd 
PatientS
Sickler A., Wang Q.C., Chawla R., Nigam S.
Independence Blue Cross, Philadelphia, PA, USA
OBJECTIVES: To determine clinical, socio-demographic and member-level fac-
tors associated with hospital readmissions in COPD patients and identify COPD 
patients at high risk of two or more hospital readmissions within 6 months post-
discharge. METHODS: Commercial and Medicare health plan members who were 
identified with COPD and incurred an index admission for a COPD-related condition 
from August 2011 through July 2013 in Southeastern Pennsylvania and surrounding 
counties were prospectively evaluated using health insurance claims and consumer 
data. COPD patients were identified using clinical diagnoses defined by Centers 
for Medicare and Medicaid Services. Readmission was defined as two or more all-
cause hospital admissions within 6 months after the index admission. Risk factors 
including but not limited to utilization, pharmacy, comorbidities, laboratory results, 
and vaccinations were examined and measured up to one year prior to the index 
admission and during the hospitalization. Socio-demographic and member-level 
factors were also evaluated for model predictability. RESULTS: Within 6 months 
post-discharge, of the 7,206 COPD patients, 7.7% had two or more readmissions. 
Bivariate analysis found that comorbidities and utilization were large predictors of 
readmissions. Additional significant factors included oxygen use, B-type natriuretic 
peptide testing, quinolone antibiotic use and education level. Multivariate analysis 
using logistic regression found prior admissions, ER visits, specialist visits, comorbid 
with cellulitis, myocardial infarction, renal disease, diabetes and low education to be 
among the highly predictive variables. The model yielded a lift of 3.1 for the top 5% of 
the population and produced a Positive Predictive Value of 27%. CONCLUSIONS: Our 
model identified specific combinations of clinical, socio-demographic and member-
level factors that improved our ability to identify COPD patients at the highest risk 
of readmission. Further research is needed to validate model results and apply 
clinical analytics into intervention and outreach programs aimed at preventing 
future readmissions.
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OBJECTIVES: To analyze the association between non-pharmacological treatment 
of substance use and mortality in elderly Medicare patients with advanced pros-
tate cancer and substance use disorder. METHODS: SEER-Medicare linked database 
between 2000 and 2009 was used. From the cohort of men diagnosed with advanced 
prostate cancer between 2001 and 2004, we identified those with a diagnosis of sub-
stance use using ICD-9 codes of 291 (Alcoholic psychosis); 292 (Drug psychoses); 303 
(Alcohol dependence syndrome); 304 (Drug dependence); and 305 (Non-dependent 
use of drugs). For this cohort of elderly with advanced prostate cancer and substance 
use, we used inpatient, outpatient and provider claims to determine non-phar-
macological treatment for substance use. The association between treatment for 
substance use and five-year mortality was analyzed using Cox regression. RESULTS: 
Of 1509 elderly with advanced prostate cancer and substance use disorder, only 
10% had a claim related to non-pharmacological treatment of substance use in 
the five-year period post-cancer diagnosis. Demographic and clinical attributes 
were comparable between those treated for substance use vs. those not treated 
for substance use. Cox regression indicated that treatment for substance use was 
associated with lower hazard of all-cause mortality, compared to those not treated 
for substance use (HR 0.63 ; 95% CI 0.46, 0.86). CONCLUSIONS: In elderly prostate 
cancer patients with substance use disorder, substance use treatment appears to 
have beneficial effect on mortality. However, the utilization of substance use treat-
ment was only moderate. Prostate cancer incidence increases exponentially with 
age and therefore, an aging population will exert significant burden on healthcare 
system. Substance use disorder remains a neglected co-morbidity in elderly cancer 
patients. Along with policies to effectively screen and treat substance use in elderly 
prostate cancer patients, policies for enhancing utilization of substance use treat-
ment by elderly cancer patients are necessary.
PHS23
relation between HealtH inSurance coverage and outcomeS among 
women witH breaSt cancer in florida
Tawk R.H.1, Ali A.2, Adunlin G.2, Xiao H.2
1Florida A&M University, Tallahassee, FL, USA, 2Florida A & M University, Tallahassee, FL, USA
OBJECTIVES: Breast cancer (BC) poses disproportionate burden of disease among 
medically underserved and minority women. African-American women continue 
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of implementation of a paediatric neurocritical care programme on outcomes after 
severe traumatic brain injury: a retrospective cohort study. The Lancet Neurology, 
Volume 12, Issue 1, p 45 – 52. January 2013.
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OBJECTIVES: The primary objectives of this study were to estimate the average costs 
during the initial phase of care (year of diagnosis) among West Virginia (WV)-Medicare 
beneficiaries with breast cancer (BC) and compare it with the national estimates from 
the Surveillance, Epidemiology, End Results (SEER)-Medicare database using a linear 
decomposition technique. METHODS: A retrospective observational study was con-
ducted where the study cohorts consisted of elderly women age > 66 with incident 
BC between 2003 and 2006 in WV-Medicare and SEER-Medicare. Total costs were the 
actual medical payments for all services derived from Medicare files. Generalized 
linear regressions with log link and gamma distribution were performed. Blinder-
Oaxaca decomposition was conducted to examine the extent to which predisposing, 
enabling, need-related, healthcare use and external healthcare environmental factors 
contributed to the differences in the average costs. RESULTS: Total average costs for 
WV-Medicare cohort during the initial phase of care were lower ($19,875) as compared 
to the SEER-Medicare cohort ($22,881), a difference of $3,006. After adjusting for other 
factors, the difference was $549 and remained significant. Only 16% of the difference 
in the average costs between the two cohorts were explained by the independent 
variables included in the model. Enabling resources (6.85%), healthcare use (7.53%) 
explained most of the differences in costs. CONCLUSIONS: Total average costs of BC 
care were lower in a rural state compared to the national estimates. The differences 
in the costs were not explained by the patient-level factors included in the model.
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OBJECTIVES: Patient care burden to health professionals (HPs) and health care 
institutions for many disorders, including agitation in schizophrenia or bipolar I 
disorder, may not be fully captured through claims data and/or medical records. 
The study objective was to assess this burden, specifically for agitated patients with 
schizophrenia and bipolar I disorder who visit emergency departments or psychiatric 
emergency service units. METHODS: This study consists of one-on-one qualitative 
telephone interviews followed by a web-based survey. Interviews are conducted with 
10 emergency setting-based HPs (physicians, nurses, aides, ED/hospital administra-
tors, and social workers). Interviews follow a semi-structured guide with specific 
probes/prompts to capture the intangible impacts that drive indirect and direct costs 
of care. The guide includes general open-ended questions and specific questions on 
specific areas of impact, including physical, psychological, and emotional impacts 
on the HP, as well as impacts on job performance and satisfaction. The interview 
findings inform a web-based survey (administered to a similar mix of 200 treating 
HPs) which includes multiple choice questions, rating questions, ranking exercises, 
and open-ended questions. The survey collects data such as characteristics of HPs, 
burden of treating patients including use of restraints, isolation, boarding, length of 
stay, staff abuse and injury, and direct costs. RESULTS: The results from the on-going 
interviews and web survey of the indirect burden of treating these patients with 
agitation will be reported. CONCLUSIONS: This interview and survey methodology 
comprehensively assesses the full burden of treating agitation in schizophrenia or 
bipolar I disorder patients from the point of view of various HPs. This study will help 
bridge the gap on the indirect burden of treating patients with agitation, and can be 
used to complement direct burden of care data. This methodology can be applied 
to other disease areas to comprehensively assess the burden of patient treatment.
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OBJECTIVES: The objective of this retrospective database analysis was to examine 
the most common reasons for hospitalization and the associated burden of these 
hospitalizations among children in the United States. METHODS: Data from the 2012 
Healthcare Cost and Utilization Project’s (HCUP) Kids’ Inpatient Database (KID) were 
assessed for this analysis. The top-10 most common primary discharge diagnoses 
(ICD-9-CM) were obtained for children aged 1-4, 5-9, and 10-14 years. The length of 
stay (LOS) and costs for each of these admissions were reported. Costs were esti-
mated based on charges and hospital specific cost-to-charge ratios. RESULTS: The 
most common primary discharge diagnoses were: children 1-4 years (N= 481,859), 
pneumonia (N= 41,716) and acute asthma exacerbation (N= 27,453); children 5-9 years 
(N= 321,535), pneumonia (N= 20,240) and acute asthma exacerbation (N= 18,147); and 
children 10-14 (N= 359,000), years acute appendicitis (N= 18,487) and affective psy-
choses (N= 13,221). Across all age groups, pneumonia, asthma, and chemotherapy 
administration were included in the top-10 most common diagnoses. For children 1-4 
years, chemotherapy administration had the greatest burden (mean LOS= 5.0 days, 
mean costs= $12,438; LOS range: 1.4 croup-2.6 pneumonia; cost range: $2,629 croup-
$5,164 acute bronchiolitis). For children 5-9 years, affective psychoses had the longest 
LOS (mean LOS= 8.1 days; range: 1.2 fractured humerus-4.8 acute appendicitis) and 
acute appendicitis had the greatest cost (mean cost= $12,104; range: $3,204 dehy-
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OBJECTIVES: This analysis evaluated the impact of non-medical switching (switch-
ing for a reason that is not medically related such as due to costs) from adali-
mumab (ADA) to another injectable biologic (certolizumab, golimumab, etanercept, 
or ustekinumab) on healthcare costs in patients with rheumatoid arthritis, psoriasis, 
psoriatic arthritis, ankylosing spondylitis, or Crohn’s disease following a formu-
lary management change by large national payor. METHODS: Medically stable 
adult patients with ≥ 90 days continuous ADA use were identified in OptumInsight 
database (07/01/2012-06/30/2013). Patients who subsequently switched to another 
biologic (index date) following a payer formulary change and for no apparent medi-
cal reason between 01/01/2013-06/30/2013 were defined as non-medical switchers. 
Patients who remained on ADA therapy during this period were defined as main-
tainers and their index dates were chosen randomly. Patients with hospitaliza-
tions, emergency department (ED) visits, or substantial increases in ADA dose 6 
months pre-index (baseline) were excluded to ensure medical stability. Outcomes 
included all-cause and indication-related medical (hospitalizations, ED visits, and 
outpatient visits) and total (medical and pharmacy) costs. T-tests and multivariate 
regression analyses were used to compare cohorts in costs incurred during the 6 
months post-index (follow-up) and in costs difference from baseline to follow-
up. RESULTS: Mean age was 46 and 48 years, respectively, for maintainers (n= 2,693) 
and switchers (n= 985). Switchers incurred significantly higher all-cause medical 
costs ($4,557 vs $3,310; P= .0011) and total costs ($21,996 vs $17,379, P< .0001) during 
follow-up vs maintainers. Differences from baseline to follow-up were significantly 
greater for non-medical switchers compared to maintainers in all-cause medical 
costs ($1,476, P< .0001) and total costs ($6,355, P< .0001). Adjusted regression analyses 
and indication-specific results yielded consistent findings. CONCLUSIONS: These 
real-world analyses of patients stabilized on ADA demonstrated that maintaining 
therapy with ADA was associated with significantly less healthcare expenditures 
compared to switching to another anti-TNF for a non-medical reason.
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OBJECTIVES: The obesity pandemic is driving an increase in healthcare utilization. 
However the specific breakdown of increased morbidity and associated usage requires 
linked primary care, chronic disease and hospitalization registries. Clalit Health 
Services (CHS), with its comprehensive stable database of over 4 million members, 
provides a strong base for comparing morbidity and health care utilization between 
obese and non-obese patients, thus laying the groundwork for informed health 
care policy. METHODS: We selected two random samples, 10,000 obese (BMI> 30 1/
Jan/2011) patients and 10,000 not-overweight (BMI< = 25) from the CHS database aged 
25-74, matching CHS population age standard. We linked both datasets to the chronic 
disease registry, identifying the following diagnoses: diabetes, ischemic heart disease 
(IHD), congestive heart failure (CHF), hypertension (HTN), s/p cerebral vascular acci-
dent (CVA), chronic renal failure (CRF), and rheumatoid arthritis (RA). We compared 
disease prevalence, hospital admission rates and total cost for the groups. RESULTS: 
The prevalence of all chronic disease The greatest effect was seen for diabetes 
(RR= 3.39 CI 3.15-3.65), CHF (2.23 1.79-2.78), and HTN (2.34 2.22-2.46) but also for IHD, 
CVA , CRF and RA (1.77, 1.69, 2 and 1.37 respectively). Risk of hospitalization over 
three years was increased (1.34 1.28-1.42) and, on average, there were 58% increase in 
hospitalizations and 303% overall increased cost of healthcare compared to non-obese 
patients. CONCLUSIONS: The presence of obesity increases risk of severe comorbidi-
ties within the general population. Obesity increases risk of any hospitalization and 
both total cost and total hospital admissions among patients. Our findings suggest 
the need for intensive proactive health care policy to prevent and remedy obesity to 
prevent the financial collapse of over-stretched health organizations, and indicate the 
potential for cost-effectiveness of interventions, whether behavioral, pharmaceutical, 
or surgical, or combinations thereof.
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OBJECTIVES: This study analyzes the costs of hospital care to children with TBI before 
and after a pediatric neurocritical care center (PNCC) implementation. A previous 
study1 with this sample showed improved clinical outcomes. METHODS: This retro-
spective cohort study includes 63 patients in the pre-PNCC group, and 59 post-PNCC 
patients. We merged demographic and clinical data with cost data from the hospital 
finance office for the same patient hospitalization. Outcome variables included total 
cost percentage ((direct + overhead)/median total cost pre-PNCC*100%), and overall 
length of stay (LOS) and PICU LOS. Mann-Whitney U’s, chi-squares, and multiple linear 
regression were utilized. RESULTS: Gender, race, injury mechanism, age at admis-
sion, Glasgow Coma Score, and PRISM III score were similar in the pre and post-PNCC 
groups (p> 0.05 for all). While PICU length of stay (LOS) increased post-PNCC (median 
(IQR) pre: 11 (5-15) v. post: 14 (7-22), p = 0.02), the overall hospital LOS did not change 
(pre: 32 (14-55) v. post 37 (17-58), p = 0.42. Total cost percentage increased from a 
median(IQR) of 100% (61-181%) to 143% (95-218%), p = 0.04. After adjusting for covari-
ates, total costs percentage was still significant post-PNCC compared to pre-PNCC 
(b(se) = 16.2(5.4), p = 0.003). LOS and PICU LOS were also positively related to total costs 
(b(se) = 2.6(0.1) and 2.6 (0.4) respectively, p < 0.0001 for both). CONCLUSIONS: After 
adjusting for PICU LOS, PNCC implementation remained associated with an increase 
in total cost. One would need to look outside of the initial hospitalization to determine 
if PNCC is cost effective given the improved clinical outcomes. 1 Pineda et al. Effect 
